We exist because the genomic data M&A market deserved a dedicated intelligence firm — one that speaks both the language of science and the language of capital.
ValeBorne was founded because traditional due diligence fails at the intersection of genomic science and M&A. Most financial analysts lack the scientific literacy to assess a multi-omics data asset. Most scientists lack the forensic financial skills to spot inflated IP valuations or revenue quality issues. The result: acquirers close on risk they cannot see.
Our team combines data scientists, financial analysts, and legal experts to deliver the deepest risk assessments available in the genomic data sector. We bring together expertise in regulatory compliance, scientific reproducibility, forensic accounting, and operational due diligence — all applied specifically to genomic data companies.
From our base in Charlotte, North Carolina, we serve private equity firms, strategic acquirers, and Big Pharma business development teams navigating one of the most technically complex M&A categories in the market today.
Our team has conducted in-depth analyses across a range of companies in the multi-omics, sequencing, and data integration sectors. Contact us for a list of recent engagements.
Every ValeBorne engagement is structured around four interlocking audit dimensions. No pillar is optional — each one has caught deal-breaking risks that the others would have missed.
Regulatory posture and intellectual property integrity.
Scientific validity and infrastructure robustness.
Forensic financial analysis beyond standard review.
Human capital and process maturity signals.
ValeBorne was built by professionals who understand both the science and the deal. Our founding team brings together strategy, technology, finance, and market development.
Ultimate strategy, fundraising, board governance, and external partner relations. Drives ValeBorne's vision and long-term positioning in genomic M&A intelligence.
Technology vision, AI/ML roadmap, and product development. Oversees data pipeline architecture, proprietary scoring models, and platform engineering.
Financial strategy, forensic modeling, cash flow management, and investor relations. Leads all financial pillar assessments in client engagements.
Brand strategy, customer acquisition, and go-to-market execution. Builds ValeBorne's presence as the definitive intelligence brand in genomic M&A.
Book a 15-minute discovery call. We'll scope the right engagement for your deal timeline — and run a complimentary demo assessment to show you what we find.
Request a Consultation View Services & Pricing